|
N-NO formation in 2-mercaptobenzothiazole
|
|
2
|
142
|
April 29, 2026
|
|
EMA's Revision of the Acceptance Limit for N-Nitroso-N-desmethyl-diphenhydramine
|
|
4
|
490
|
April 20, 2026
|
|
Potential for Nitrosamines in Medical Device Combination Products - Letter to Industry(FDA)
|
|
4
|
231
|
April 20, 2026
|
|
Maximum Daily Dose (MDD) of Cream Formulation
|
|
1
|
258
|
April 17, 2026
|
|
Stability Assessment of FDA Approved Varenicline Tartrate Products for Critical Quality Attributes – N-Nitroso Varenicline, Solid Form, and Dissolution-Pub
|
|
2
|
145
|
April 14, 2026
|
|
Determination of N-nitroso Caspofungin
|
|
1
|
141
|
March 27, 2026
|
|
Mutagenicity of EAT-positive NDSRIs in HepaRG spheroids-Pub
|
|
0
|
92
|
March 20, 2026
|
|
Minimizing in Source Fragmentation for Mass Spectrometry Based NDSRI Analytical Procedures: A Case Study of Nitroso-bumetanide -Pub
|
|
4
|
368
|
March 19, 2026
|
|
Testing of N-nitroso-cinacalcet
|
|
8
|
1206
|
March 14, 2026
|
|
Navigating the complexities in characterization of NDSRIs using advanced analytical techniques-Pub
|
|
2
|
279
|
March 12, 2026
|
|
N-Nitrosodibenzylamine infusion bags
|
|
0
|
132
|
February 27, 2026
|
|
👨💻 Quantitation of N-Nitrosodimethylamine (NDMA) and N-Nitrosophenylephrine (NNPE) in Phenylephrine Hydrochloride (API) by LC-MS/MS
|
|
0
|
435
|
February 7, 2026
|
|
👨💻 N-Nitroso-Propranolol Test Method & Validation Report
|
|
0
|
200
|
February 7, 2026
|
|
👨💻 N-Nitroso-Methylphenidate Test Method and Validation Report
|
|
0
|
186
|
February 7, 2026
|
|
Ames Concordance with the In Vivo Transgenic Rodent (TGR) Gene Mutation Assay for NDSRIs and Relative In Vivo TGR Potency with Nitrosamines with Robust Dose-Response Carcinogenicity Data-Pub
|
|
1
|
252
|
February 5, 2026
|
|
Available Tools for Prediction of Potential Degradation Products from Nitrosation Reactions
|
|
4
|
329
|
February 4, 2026
|
|
N-nitroso-rivaroxaban amide
|
|
7
|
2137
|
February 4, 2026
|
|
TGA updated Established acceptable intake for nitrosamines in medicines on 29 January 2026
|
|
0
|
470
|
January 29, 2026
|
|
Nitrosamine Drug Substance-Related Impurities cause DNA methylation adducts in vitro and in primary hepatocytes upon Cytochrome P450-dependend metabolic activation-Pub
|
|
2
|
271
|
January 29, 2026
|
|
Sufentanil Nitroso impurity standard
|
|
8
|
267
|
January 29, 2026
|
|
Nitrosamine Impurities: The Analytical & Regulatory Roadmap (2024-2025)
|
|
0
|
464
|
January 20, 2026
|
|
N-nitrosamides, N-nitrosoureas, Nnitrosoguanidines
|
|
7
|
644
|
December 30, 2025
|
|
Establishing Best Practice for N- Nitrosamine Read-Across and Surrogate Selection
|
|
0
|
179
|
December 22, 2025
|
|
N-Nitroso Abemaciclib
|
|
13
|
1008
|
December 22, 2025
|
|
N-Nitroso vonoprazan
|
|
1
|
372
|
December 15, 2025
|
|
Nitrosamines in macrocyclic antibiotics
|
|
2
|
282
|
December 10, 2025
|
|
Issue Regarding Purchase of N-Nitroso N-Desmethyl Rosuvastatin Reference Standard
|
|
5
|
338
|
December 10, 2025
|
|
Issue with Area Drop During N-Nitroso Dorzolamide Method Setup
|
|
3
|
244
|
December 10, 2025
|
|
NDSRI in Pyrathiazine theocolate
|
|
3
|
358
|
December 5, 2025
|
|
WHO Updates on Nitrosamine Impurities
|
|
3
|
758
|
December 3, 2025
|